Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Multicenter, Non-Comparative, Prospective Observational Study to Evaluate Efficacy and Safety of Combined Ribavirin and Peginterferon Alfa-2a (40 kDa) Therapy in Patients With Chronic Hepatitis C (CHC) or Compensated Liver Cirrhosis in Real Clinical Practice

NCT01609049 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01609049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01609049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Multicenter, Non-Comparative, Prospective Observational Study to Evaluate Efficacy and Safety of Combined Ribavirin and Peginterferon Alfa-2a (40 kDa) Therapy in Patients With Chronic Hepatitis C (CHC) or Compensated Liver Cirrhosis in Real Clinical Practice
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
December 7, 2011
Completion date
June 22, 2015
Enrollment
1,496 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic